FDA Replaces 'Artificial Intelligence' with 'Super Intelligence' in Official Documents Following Executive Order
Effective November 16, 2026, the U.S. Food and Drug Administration (FDA) has officially transitioned from using the terms 'Artificial Intelligence' (AI) to 'Super Intelligence' (SI) in its public-facing documents, digital communications, and web portals. This administrative change is in direct response to White House Executive Order 14434, signed by President Trump on September 29, 2026, which mandates executive departments and regulatory agencies to adopt the new terminology. The FDA has clarified that this nomenclature shift is purely administrative and does not alter existing regulatory requirements, review standards, or submission pathways for medical product sponsors and academic clinical trial investigators. The legal scope of 'Super Intelligence' under this order aligns with the statutory definition of artificial intelligence established in 15 U.S.C. 9401(3) by the National Artificial Intelligence Initiative Act of 2020, meaning it does not imply a higher capability threshold or require a demonstrat...